Recent Updates
Recently added Catalysts
IMRX Positive Sentiment

Ben Zeskind, Ph.D., MBA

Thursday, December 18, 2025 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Dr. Ben Zeskind has been a pivotal leader at IMRX since its founding in 2008. He holds an S.B. in electrical engineering and computer science from MIT, a Ph.D. in bioengineering, and an MBA from Harvard Business School, where he earned the distinction of Baker Scholar.
Price reaction · baseline $5.5 (2025-12-17 close) · hit after-hours · 7 other IMRX headline(s) in the window, move may be shared
day 0 close · peak
+3.1%

Market Sentiment Analysis

POSITIVE FACTORS

  • Dr. Zeskind has extensive educational qualifications from prestigious institutions.
  • He has been a key figure in the company since its inception.
  • His leadership role has been consistent since February 2008.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+41%
120-day peak, hindsight
Typical move
11.4%
average across 8 past catalysts
Cash runway
~36 mo
Minimal dilution risk
Lead asset
IMM-1-104 Monotherapy
Phase 1 · Advanced Solid Tumor

Full Press Release Details

Dr. Zeskind has served as our Co-Founder, President, Chief Executive Officer and a member of our board of directors since February 2008. Dr. Zeskind received his S.B. in electrical engineering and computer science and his Ph.D. in bioengineering from Massachusetts Institute of Technology, or MIT, and his M.B.A. from Harvard Business School, where he was recognized as a Baker Scholar, the highest award for distinction.

Frequently Asked Questions

What roles has Dr. Zeskind held at IMRX?

Dr. Zeskind has served as Co-Founder, President, CEO, and board member since 2008.

Where did Dr. Zeskind receive his education?

He earned his degrees from MIT and Harvard Business School.

What is the Baker Scholar distinction?

The Baker Scholar is the highest award for distinction at Harvard Business School.

ShareAdd on Google
Tags: IMRX Viatris Investor Conferences Healthcare Ben Zeskind bioengineering Harvard Business School MIT
Last updated: Dec 18, 2025

Biotech snapshot

Cash runway
$202M liquidity · $6M/mo burn
~36 mo
Minimal dilution risk
Lead asset
IMM-1-104 MonotherapyPhase 1
Advanced Solid Tumor →

Catalyst track record

+41%
best trade around IMRX's most recent catalyst

Peak hindsight return over a 120-day window, across 8 tracked FDA/PDUFA catalysts for IMRX.

See every catalyst's timing & PoA →